Role of plasmacytoid dendritic cells in humoural and CD8+ T-cell memory responses following BNT162b2 mRNA vaccination: a preclinical mouse study

BACKGROUND: The Pfizer-BioNTech coronavirus vaccine (BNT162b2) was among the first nanoparticle-based vaccines approved by the World Health Organisation (WHO) and demonstrated 95% efficacy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Despite its success, the precise immune mechanism behind its effectiveness remains poorly understood. This study investigated the early immune responses occurring in the draining lymph node (dLN) following vaccination. METHODS: A well-established murine vaccination model was used to investigate the distribution and immunological effects of BNT162b2 in vivo. Vaccine trafficking to the dLN, cellular uptake, and spike protein expression were assessed following immunisation. Single-cell transcriptomic analyses and functional in vivo experiments were performed to identify the immune cell populations involved in orchestrating vaccine-induced responses and to characterise their interactions with adaptive immune cells. FINDINGS: T-cell activation and expansion, indicating an involvement in shaping adaptive immunity following vaccination. INTERPRETATION: T-cell activation, pDCs appear to play a functional role in the efficacy of this mRNA vaccine. This study provides additional insights into the immunological processes underlying mRNA vaccine-induced protection and may inform the future design and optimisation of mRNA-based immunotherapies and vaccines. FUNDING: Swiss National Science Foundation, Leonardo Foundation.

Authors

Institutions

Publication Details

Journal
EBioMedicine
Published
2026-08-21
DOI
https://doi.org/10.1016/j.ebiom.2026.106432
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Role of plasmacytoid dendritic cells in humoural and CD8+ T-cell memory responses following BNT162b2 mRNA vaccination: a preclinical mouse study

Alain Pulfer, Tommaso Virgilio, Luciano Cascione, Charaf Benarafa et al.
EBioMedicine
Immunotherapy and Immune Responses
article

Role of plasmacytoid dendritic cells in humoural and CD8+ T-cell memory responses following BNT162b2 mRNA vaccination: a preclinical mouse study

Alain Pulfer, Tommaso Virgilio, Luciano Cascione, Charaf Benarafa, Santiago González, Melanie Brügger, Simone G. Moro, Daniel F. Legler, Irene Latino, Kamil Chahine, Chiara Pizzichetti, Giorgia Bilato, Nedim Kozarac, Arianna Capucetti, Roshan S. Thakur, Louis Renner
article en

Abstract

BACKGROUND: The Pfizer-BioNTech coronavirus vaccine (BNT162b2) was among the first nanoparticle-based vaccines approved by the World Health Organisation (WHO) and demonstrated 95% efficacy against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Despite its success, the precise immune mechanism behind its effectiveness remains poorly understood. This study investigated the early immune responses occurring in the draining lymph node (dLN) following vaccination. METHODS: A well-established murine vaccination model was used to investigate the distribution and immunological effects of BNT162b2 in vivo. Vaccine trafficking to the dLN, cellular uptake, and spike protein expression were assessed following immunisation. Single-cell transcriptomic analyses and functional in vivo experiments were performed to identify the immune cell populations involved in orchestrating vaccine-induced responses and to characterise their interactions with adaptive immune cells. FINDINGS: T-cell activation and expansion, indicating an involvement in shaping adaptive immunity following vaccination. INTERPRETATION: T-cell activation, pDCs appear to play a functional role in the efficacy of this mRNA vaccine. This study provides additional insights into the immunological processes underlying mRNA vaccine-induced protection and may inform the future design and optimisation of mRNA-based immunotherapies and vaccines. FUNDING: Swiss National Science Foundation, Leonardo Foundation.

EBioMedicineVol. 131
University of Insubria (IT), University of Bern (CH), Biotechnology Institute Thurgau (CH), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Università della Svizzera italiana (CH)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zero hunger
Openalex Percentile: Top 16%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.